Burkitt’s Lymphoma in a patient with systemic lupus erythematosus

Jyotsna Laxmikant Oak, Laxmi Patil, Sandeep Goyle
DOI: 10.15305/ijrci/v4i1/209

Abstract

Recent literature evidence has demonstrated a small but definite increase in the risk of malignancies in SLE patients when compared to general population. The present case study reports a rare occurrence of Burkitt’s lymphoma in a 32-year-old female patient who had been diagnosed with SLE around 3 years ago. The study also discusses the possible pathophysiological links between Burkitt’s lymphoma and SLE.


Citation

Oak JL, Patil L, Goyle S. IJRCI. 2016;4(1):CS7 DOI: 10.15305/ijrci/v4i1/209

Keywords

SLE, Burkitts Lymphoma

References

1. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001; 13(5): 345–351.

2. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005; 165(20): 2337–2344.

3. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin J-F, Joseph L, Lachance S, et al. Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005; 64(10): 1507–1509.

4. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978; 89(6): 888–892.

5. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum. 1996; 39(6): 1050–1054.

6. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992; 51(4): 437–439.

7. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005; 52(5): 1481–1490.

8. Ott G, Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica. 2008; 93(12): 1773–1776.

9. Bernatsky S, Ramsey-Goldman R, Gordon C, Manzi S, Nived O, Bae SC, et al. Histology, prognostic factors, treatment, and outcome in SLE patients with non-Hodgkins lymphoma [Abstract]. Arthritis and Rheumatism. 2009; 60 (Suppl): S1933.

10. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol. 2011; 7(6): 360–368.

11. Löfström B, Backlin C, Pettersson T, Lundberg IE, Baecklund E. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2011; 38(9): 1891–1897.

12. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004; 172(5): 3268–3279.

13. Bellier C, Khellaf M, Lambotte O, Godeau B. Burkitt’s lymphoma in a patient with systemic lupus erythematosus treated with immunosuppressive drugs. A case report. Rev Med Interne. 2006; 27(3): 244–247.

14. Posner MA, Gloster ES, Bonagura VR, Valacer DJ, Ilowite NT. Burkitt’s lymphoma in a patient with systemic lupus erythematosus. J Rheumatol. 1990; 17(3): 380–382.

15. Chang DK, Yoo DH, Kim TH, Kim IS, Jun KY, Park MH, et al. Burkitt’s lymphoma presenting as ileocaecal intussusception in systemic lupus erythematosus. Clin Rheumatol. 1999; 18(3): 253–256.

16. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest ;1997; 100(12): 3019–3026.

17. Draborg AH, Duus K, Houen G. Epstein-Barr Virus in Systemic Autoimmune Diseases. Clin Dev Immunol. 2013:535738.

18. Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin J-F, Costenbader KH, Urowitz MB, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014; 73(1): 138–42.